Scholarlink

<p>Cellular senescence (CS) is a crucial tumor-suppressive phenomenon, inhibiting proliferation of cancerous cells. However, cancer therapies can also induce tumor cell senescence, generating senescent cells in tumoral and normal tissues. While initially beneficial, these senescent cells can paradoxically contribute to tumor recurrence, metastasis, and therapy resistance via the senescence-associated secretory phenotype (SASP). Due to the diverse and critical roles, cellular senescence could be a potential target in cancer biomedicine. To extend our understanding of therapy-induced senescence (TIS), developing experimental models is necessary. Currently TIS established models can be categorized into animal-based and laboratory models. These models are essential for advancing our knowledge of aging mechanisms and developing new treatment modalities. In vivo models of TIS have faced limitations, including poor immune system representation, oversimplified stromal complexity, and an inability to model functional vascular networks. Incorporating cutting-edge technologies such as 3D cultures, co-culturing, and tissue engineering can help researchers in creating in vitro models that closely mimic physiologically conditions. This review highlighted the current TIS challenges and advanced senotherapeutics. Finally, we discussed how to develop reliable in vitro models to better understanding TIS mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

3D models to study therapy-induced senescence: where do we stand now?

  • 期刊论文

  • 发表日期：

    2025年7月8日

查看全文
  • Zahra Heydari,
  • Alexander Malogolovkin,
  • Olga Smirnova,
  • Damir Lyukmanov,
  • Alina Filimonova,
  • Anastasia Shpichka,
  • Massoud Vosough,
  • Peter Timashev

摘要

Cellular senescence (CS) is a crucial tumor-suppressive phenomenon, inhibiting proliferation of cancerous cells. However, cancer therapies can also induce tumor cell senescence, generating senescent cells in tumoral and normal tissues. While initially beneficial, these senescent cells can paradoxically contribute to tumor recurrence, metastasis, and therapy resistance via the senescence-associated secretory phenotype (SASP). Due to the diverse and critical roles, cellular senescence could be a potential target in cancer biomedicine. To extend our understanding of therapy-induced senescence (TIS), developing experimental models is necessary. Currently TIS established models can be categorized into animal-based and laboratory models. These models are essential for advancing our knowledge of aging mechanisms and developing new treatment modalities. In vivo models of TIS have faced limitations, including poor immune system representation, oversimplified stromal complexity, and an inability to model functional vascular networks. Incorporating cutting-edge technologies such as 3D cultures, co-culturing, and tissue engineering can help researchers in creating in vitro models that closely mimic physiologically conditions. This review highlighted the current TIS challenges and advanced senotherapeutics. Finally, we discussed how to develop reliable in vitro models to better understanding TIS mechanisms.